Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
GENOCEA BIOSCIENCES, INC. (GNCA) Create: Alert

All | News | Filings
Date FiledTypeDescription
06/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/24/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o...
04/28/2022 8-K Cost Associated with Exit or Disposal Activities, Regulation FD Disclosure, Financial Statements and Exhibits &nbs...
Docs: "Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives"
03/10/2022 8-K Quarterly results
03/07/2022 8-K Quarterly results
01/04/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "Genocea Biosciences Provides Corporate Update"
10/28/2021 8-K Quarterly results
Docs: "Genocea Provides Third Quarter 2021 Corporate Update GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues"
09/13/2021 8-K Quarterly results
07/29/2021 8-K Quarterly results
Docs: "Genocea Provides Second Quarter 2021 Corporate Update GEN-011 neoantigen-targeted peripheral T cell therapy clinical trial continues"
07/13/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Genocea Doses First Patient in Phase 1/2a TiTAN Clinical Trial for GEN-011 Neoantigen-Targeted T cell Therapy"
06/24/2021 8-K Quarterly results
06/04/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
Docs: "Genocea Provides First Quarter 2021 Corporate Update GEN-011 and GEN-009 immuno-oncology programs continue to advance"
04/14/2021 8-K Quarterly results
02/11/2021 8-K Quarterly results
01/04/2021 8-K Quarterly results
11/18/2020 8-K Investor presentation
Docs: "0 3 6 8 10 12 14 16 18 20 22 24"
11/09/2020 8-K Investor presentation
Docs: "GEN-009 Part B SITC"
11/09/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Genocea Presents Positive GEN-009 Clinical Results, Update on GEN-011 Program and New InhibigenTM Mechanism of Action Data at Virtual SITC 2020 Novel clinical and durable immune response patterns suggest addition of GEN-009 may offer additive clinical benefit in combination with PD-1-based therapies"
10/29/2020 8-K Quarterly results
Docs: "Genocea Provides Third Quarter 2020 Corporate Update Initiated GEN-011 Phase1/2a clinical trial Presented positive follow-up GEN-009 Part B data at ESMO Virtual Congress 2020 demonstrating potential added benefit to PD-1 inhibitor therapy"
09/22/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
07/30/2020 8-K Quarterly results
07/30/2020 8-K Quarterly results
07/23/2020 8-K Quarterly results
07/22/2020 8-K Quarterly results
07/20/2020 8-K Quarterly results
07/06/2020 8-K Quarterly results
06/19/2020 8-K/A Submission of Matters to a Vote of Security Holders  Interactive Data
06/02/2020 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders...
Docs: "Certificate of Amendment to Restated Certificate of Incorporation of Genocea Biosciences, Inc",
"Genocea Biosciences, Inc. Amended and Restated 2014 Equity Incentive Plan"
05/22/2020 8-K Other Events, Financial Statements and Exhibits
Docs: "Amendment to Proxy Statement"
05/12/2020 8-K Quarterly results
04/30/2020 8-K Quarterly results
Docs: "Genocea Provides First Quarter 2020 Corporate Update Clinical stage programs GEN-009 and GEN-011 continue to advance Anticipate GEN-011 IND filing in Q2 Expect GEN-009 Phase 1/2a Part B readout in Q3 GEN-011 Virtual Symposium planned for May 12 th Conference call today at 8:30 a.m. EDT"
02/13/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy